Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BMY

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga

What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report

Bristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in earnings.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Although Bristol-Myers Squibb has outshined relative to the healthcare sector over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Bristol-Myers Stock?

Bristol-Myers has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report

Bristol-Myers Squibb is poised to announce its first-quarter results this month, and analysts predict a triple-digit growth in the company’s bottom-line figure.

Barchart

Is Bristol-Myers Stock Outperforming the Dow?

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Healthcare Stocks Tackling America’s Biggest Medical Challenges

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare spending and innovative technologies transforming patient care, companies like AbbVie (ABBV), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY) are tackling some of the biggest challenges and could be poised for long-term growth. Read more….

StockNews.com

3 Precision Medicine Stocks That Could Transform Healthcare

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine industry is expected to witness significant growth and expansion. Hence, it could be wise to invest in quality precision medicine stocks Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) that are transforming…

StockNews.com

Weak Guidance from Bristol-Myers Could Be Creating an Opportunity

Bristol-Myers stock fell after earnings, but analysts remain bullish which suggests that any dip in the stock may create a buying opportunity

MarketBeat

3 High-Conviction Stocks with Strong Buy Ratings from Analysts

It’s easy to get caught up in market noise, but investing in companies backed by strong fundamentals and long-term growth potential can help investors stay the course even during market volatility. Thus, one could consider adding these three high-conviction pharmaceutical stocks, AbbVie (ABBV), Merck & Co. (MRK), and Bristol-Myers Squibb…

StockNews.com

What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

Barchart

Earnings Preview: What To Expect From Bristol-Myers Squibb's Report

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth dip in the company’s bottom-line figure.

Barchart

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Why This Dividend Stock Just Scored a Rare Upgrade

Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships.

StockNews.com

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

Barchart

Is Bristol-Myers Squibb Stock Outperforming the Nasdaq?

Although Bristol-Myers Squibb has outperformed the broader Nasdaq index over the past three months, analysts remain cautious about its growth prospects.

Barchart

What's Behind the Insider Buying on This High-Yield Stock?

As the biopharma industry booms with breakthrough treatments and growing demand, this high-yield healthcare stock just received a strong vote of confidence from insider buying.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Bristol-Myers Stock: Is Wall Street Bullish or Bearish?

Bristol-Myers has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Bristol-Myers Squibb's Quarterly Earnings Preview: What You Need to Know

Bristol-Myers Squibb is gearing up to release its third-quarter earnings at the end of this month, and analysts expect a double-digit profit dip.

Reason

No Civil Court Claim Over Publicizing Religious Court's Statement That Litigant Refuses to Appear in the Religious Court

Plaintiff had argued that defendants' publicizing the religious court's statement "serves as a form of social pressure, calling on the community to shun or ostracize the individual until they comply with the court's demands."

StockNews.com

3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst economic shifts, rising chronic illnesses, and strong growth projections in global revenues and biotechnology markets. Therefore, it could be wise to invest in pharma stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead…

Investors Business Daily

Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Breaks Out

Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock jumped, trying to break out.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the S&P 500?

Bristol-Myers Squibb has underperformed the S&P 500 over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.